AlphAIalphai — Financial news for AI agents
benzinga.comAUG 74 min read$TEM

Why Is Tempus AI Stock Surging on Friday? - Tempus AI (NASDAQ:TEM)

Tempus AI Inc. (NASDAQ:TEM) shares rose about 11% on Friday, outperforming the Nasdaq and the Healthcare sector, amid an AI-healthcare sector rally. The move followed strong peer results, including Doximity’s fiscal Q1 revenue of $156.6 million, and a strategic collaboration with CellCarta adding Tempus to its CDx lab network. TEM traded near $50.95.

Original reporting
benzinga.com
Published Aug 7, 2026, 6:21 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 11:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Why Is Tempus AI Stock Surging on Friday? - Tempus AI (NASDAQ:TEM) — source image
Source · benzinga.com
Decision brief

The 30-second read

$TEMBullishMed
01

Why it matters

For traders, the actionable elements are the same-day collaboration catalyst plus clearly stated technical inflection levels (50-day SMA zone, $46.50 support, $54.50 resistance).

02

Market read

TEM’s upside attempt is being traded as a momentum plus catalyst setup, but the stock is still below longer-term trend measures.

03

What to watch

Longer-term trend pressure remains because TEM is still about 13% below its 200-day SMA and a prior death cross can cap rallies.

Relevance 7/10Novelty 6/10Timing: Friday intraday surge with same-day catalyst details (CellCarta collaboration) and live technical levels.

Background

The article frames TEM’s surge as part of an AI-healthcare rally, citing peer earnings and a newly announced CellCarta collaboration.

Company-level read

Ticker impact

$TEMBullishMedium confidence
Context

Tempus AI shares jumped about 10.49% to $50.95 after CellCarta added Tempus to its CDx Commercialization Lab Network and peers rallied on earnings.

Expected impact

Bias to continued upside attempts while TEM holds the 50-day SMA zone near $51 and key support around $46.50; failure there could revert toward longer-term resistance near $54.50.

Evidence & confidence

The article cites a same-day collaboration catalyst and quantifies technical levels (20-day, 50-day, 200-day SMAs, support/resistance) that frame follow-through vs mean reversion.

Market effects

Sector

AI-healthcare names can see read-across momentum when a peer’s earnings and guidance spark sector-wide buying.

Regional

US index gains (Nasdaq and S&P 500 up) suggest the move is partly macro/risk-on, not purely idiosyncratic.

Global

Limited direct global linkage beyond the US-listed AI-healthcare sector rally.

Counterpoint

What could challenge this read

The move may be more sector beta than TEM-specific fundamentals, since the article emphasizes peer earnings-driven sector momentum.

Key entities

  • company
    Tempus AI Inc.

    NASDAQ-listed AI-healthcare company whose shares rose sharply on Friday alongside a CellCarta collaboration announcement.

  • company
    CellCarta

    Announced Tempus as a second commercial laboratory partner in its CDx Commercialization Lab Network.

  • company
    Doximity Inc.

    Peer whose earnings and guidance are cited as sparking broader AI-healthcare sector momentum.

Read at source← All news

Related articles

AUG 3
$TEMMed

BTIG cuts Tempus AI stock price target to $70 on model update

BTIG cut its Tempus AI (NASDAQ:TEM) price target to $70 from $80 while keeping a Buy rating after the company’s Q2 2026 earnings call. Tempus AI reported 22% YoY revenue growth, raised 2026 revenue guidance to 25% to 26%, and posted $382.5M revenue with an adjusted EPS loss of $0.04. BTIG cited Tempus’s $1.5B Personalis deal with a $46 stock-price termination trigger.

investing.com3 min
JUL 31
$TEMMedAI 8/10

Dear Tempus AI Stock Fans, Mark Your Calendars for July 30

Tempus AI (NASDAQ: TEM) agreed to acquire Personalis (PSNL) for $16.25 per share in stock, valuing the deal at about $1.5 billion enterprise value net of Tempus’ existing stake, with closing expected late 2026 or early 2027. Tempus expects integration to expand MRD capabilities. After the July 20 announcement, TEM fell 7.74% intraday. In Q1, revenue rose 36.1% to $348.12M. Needham reiterated Buy at $75; consensus target is $66.75.

yahoo.com5 min
JUL 31
$TEMMedAI 8/10

Tempus AI Raises FY2026 Sales Guidance to $1.595B-$1.605B

Tempus AI (NASDAQ: TEM) has raised its full-year 2026 sales guidance, signaling robust demand for its artificial intelligence-driven healthcare solutions. The company updated its revenue outlook to a range of $1.595 billion to $1.605 billion, an increase from the previous guidance of $1.590 billion to $1.600 billion.

scanx.trade5 min
JUL 30
$TEMMedAI 8/10

Tempus AI Q2 Results: Revenue rises 22% YoY, stock slides

Tempus AI (NASDAQ: TEM) reported second-quarter revenue of $382.5 million, rising 22% year-over-year and surpassing Street consensus estimates of $379.7 million. Despite the top-line beat and a narrower-than-expected loss per share of four cents versus an estimated 14 cents loss, shares declined 2.4% in after-hours trading to $43.25.

scanx.trade5 min
JUL 30
$TEMMed

Why Nancy Pelosi-Owned Tempus AI Stock Is Down After Q2 Earnings - Tempus AI (NASDAQ:TEM)

Tempus AI (NASDAQ:TEM) reported second-quarter financial results Thursday after market close. Here are the key highlights. • Tempus AI stock is facing resistance. Why are TEM shares declining? Tempus AI Q2 Earnings Tempus AI revenue was $382.5 million in the second quarter, up 22% year-over-year. The revenue total beat a Street consensus estimate of $379.7 million, according to data from Benzinga Pro. Revenue for the Diagnostics segment was $289.3 million, up 20% year-over-year.

benzinga.com4 min